Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
Platelets Journal shared a post on LinkedIn about a recent article by Fumiya Wada et al, published in Platelets, adding:
“Recently published in Platelets!
‘Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP’ by Fumiya Wada, et al. (2026).
This case report follows a 53-year-old woman with refractory immune thrombocytopenia (ITP) who had cycled through numerous therapies without lasting benefit.
Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, produced a partial response and when supplemented with the TPO-RA eltrombopag, the combination contributed to a sustained response.
Remarkably, after stopping efgartigimod at 22 weeks, remission continued for a further 24 weeks on eltrombopag alone.
The authors also tracked immature platelet indices throughout, observing a reciprocal shift, with IPF percent falling while AIPF rose, mirroring recovering platelet counts (see Figure 2, below).
This suggests that combining IgG depletion with enhanced platelet production may act synergistically in ITP, and these indices might serve as practical biomarkers for monitoring treatment response.”
Title: Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP
Authors: Fumiya Wada, Hiroyuki Matsui, Takuji Nakamura, Tomomi Satoh-Nakamura, Yutaka Shinkawa, Hisanori Umehara, Akifumi Takaori-Kondo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning